|
||||||||||||||||||||||||
| Join Our Email List | Monday, July 07, 2008 | ||||||||||||||||||||||||
Find Information on a:
View all Postings for:
Search ClotCare
|
Continuing Education OpportunitiesClotCare Online Resource does not offer continuing education credit. We do, however, provide information and links to continuing education opportunities that we feel may be of value to our users. We hope you find this list useful. If you know of a continuing education opportunity that you feel may be useful to other ClotCare users, please tell us about it. You may contact us at webmaster@clotcare.com. If you are specifically interested in anticoagulation training programs, check out our Training Programs page. The University of Illinois at Chicago Office of Continuing Education and Meeting Services-Programs offers a number of continuing education opportunities relating to anticoagulation and antithrombotic therapy. To review current opportunities, go to http://www.pharmacyce.uic.edu/Public/Catalog/ Thrombosis-Consult.com has a Free CME section that lists a number of Thrombosis-related CME opportunities. These listings are located at http://thrombosis.freecme.com/gallcourses.php ThrombosisClinic.com is a continuing medical education resource for health care professionals emphasizing the latest in emerging approaches in the diagnosis, treatment, and prevention of thrombosis. Visit http://www.ThrombosisClinic.com for more information.
HemostasisCME.org offers a number of continuing education opportunities relating to thrombosis. Visit http://www.hemostasiscme.org/ Additional CE Opportunities
Programs no Longer Offering Credit
North American Thrombosis Forum Traveling FellowshipApplication Deadline: July 15, 2008 The North American Thrombosis Forum is awarding one $5,000 fellowship to cover lodging and travel for a physician (either Junior Faculty or physicians-in-training), scientist, nurse, or pharmacist to explore cross-disciplinary diagnosis, treatment, education, and research related to thrombosis.
More information and online application available on NATF's website at: Thrombosis Summit 2008 - N. American Thrombosis Forum
New Insights Into Coagulation: Cancer
Date: October 31, 2008 Arterial and venous thromboses are frequent complications of cancer. Thromboses occur due to multiple different mechanisms including malignant cells, and pathobiological reactions to these cells. New and aggressive therapies themselves designed to treat cancer also may increase the risk of thrombosis. Hemorrhage and bleeding may also occur. This conference will describe and highlight some of the many complications of cancer associated with abnormal coagulation. Additional details coming soon. Beginning Preceptorship in the Management of Anticoagulation Therapy and Clinical ThrombosisWhen: November 6, 2008 Where: Albuquerque, New Mexico Description: A one-day course for physicians, nurses, and pharmacists who are newcomers to the field of anticoagulation. This introductory course covers clinical and operational aspects of care and will be helpful to providers putting together an anticoagulation clinic, or just entering this field of medicine. It is recommended as a prerequisite for the Advanced Preceptorship if you are new to the science of thrombosis. Registration fee also includes breakfast, lunch, and participation in the New Mexico Thrombosis Journal Club dinner meeting the evening of November 6, a Thrombosis Primer, and a useful course syllabus. Credit Designation: The Lovelace Clinic Foundation designates this educational activity for a maximum of 7.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The beginning course is also designated for up to 7.25 contact hours for nurses and 0.725 CEUs for pharmacists. Download brochure & registration form.
More Information: http://secure.lcfresearch.org/lcfhome/ New Mexico Thrombosis Journal Club DinnerWhen: November 6, 2008 Where: Albuquerque, New Mexico Description: An opportunity to discuss current research in the field of thrombosis with our faculty, national conference guests, and professionals from the region. The fee for this dinner is included in the fee for the Management of Anticoagulation Preceptorships, or may be purchased separately. Credit Designation: The Lovelace Clinic Foundation designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The journal club is also designated for up to 1.0 contact hour for nurses and 0.100 CEU for pharmacists. Download brochure & registration form.
More Information: http://secure.lcfresearch.org/lcfhome/ Advanced Preceptorship in the Management of Anticoagulation Therapy and Clinical ThrombosisWhen: November 7-8, 2008 Where: Albuquerque, New Mexico Description: A highly acclaimed, 2-day, in-depth course for those practicing in, or those newly responsible for setting up, anticoagulation clinics. This course is limited to 50 registrants to ensure high interaction with our expert faculty. The registration fee includes participation in the New Mexico Thrombosis Journal Club on November 6, a reception on November 7, a clinic site tour, breakfast and lunch each day, a Thrombosis Primer, and useful course syllabus. Credit Designation: The Lovelace Clinic Foundation designates this educational activity for a maximum of 15.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. The advanced course is also designated for up to 15.25 contact hours for nurses and 1.525 CEUs for pharmacists. Download brochure & registration form.
More Information: http://secure.lcfresearch.org/lcfhome/ Real World Best Practices for DVT ProphylaxisCME Credit hours: 1.5 AMA PRA Category 1 credits
Release date: July 25, 2006 Program DescriptionVenous thromboembolism (VTE) is a major cause of morbidity and mortality in the United States. While unfractionated heparin (UFH) has been the standard treatment of VTE for many years, low-molecular-weight-heparins (LMWHs) are now commonly used as a therapeutic alternative. Effective prophylaxis and intervention are essential in minimizing VTE risk and reducing the incidence of life-threatening events. There exists a gap in knowledge for the treatment of VTE with secondary prophylaxis, acute PE, as well as a special consideration for the critically ill (e.g. volume overloaded) or patients with comorbidities (e.g. renal insufficiency). Furthermore, the existing clinical data needs to be discussed and interpreted in order to be applied, as well as a discussion surrounding current issues and controversies in VTE treatment and prophylaxis. This program provides concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE. Target AudienceThis activity is intended for healthcare providers who treat DVT. Educational ObjectivesUpon completion of this educational activity participants will be able to:
Faculty
View Program
The program is available online at: Challenges in Dosing Low Molecular Weight HeparinCME Credit hours: 1.0
Release date: November 15, 2005 Program DescriptionAnticoagulants are used in a wide variety of patients, for both therapeutic purposes and as prophylaxis against thromboembolism. The efficacy of these agents has been well established in clinical trials. Unfractionated heparin can be hard to use, it binds to plasma proteins, and so there is wide variation in its anticoagulant effect. Vigilant monitoring of the PTT is necessary. Heparin-induced thrombocytopenia occurs about 3% of the time and this can be a big problem when it occurs. Low molecular weight heparins are produced by depolymerization of unfractionated heparin, rendering them smaller and thus more bioavailable. There is less binding to plasma proteins and less inactivation by platelet factor 4. Because of their more predicable effects, routine laboratory monitoring for dose adjustment is usually not required. There are solid clinical trial data indicating that low molecular weight heparins can be used as an alternative to unfractionated heparins. This program’s intention is NOT to review those data. Instead, this program features a discussion between four experts in critical care medicine. The discussion addresses the challenges in dosing and monitoring patients at the extremes of body weight, patients with renal insufficiency, and critically ill patients with altered plasma volume. Target AudienceThis activity is intended for Cardiologists, Hematologists, Intensivists, Pharmacists and other healthcare professionals who treat patients with LMWH. Educational ObjectivesUpon completion of this activity, participants will be able to:
Faculty
View Program
The program is available online at: Cancer and ThromboembolismPharmion Corporation has provided ClotCare Online Resource with a publication written by Joseph A. Caprini, MD, MS, FACS, RVT. This case presentation and discussion is entitled Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion. If you are interested in receiving CME credit for reviewing this publication, simply complete the questions provided and follow the instructions that accompany them. You will need Adobe Reader to view this document. You may download a free copy from Adobe's website at http://www.adobe.com/products/acrobat/readstep2.html. Read Management of Thromboembolism in Cancer Patients: A Case Presentation and Discussion |
|||||||||||||||||||||||
|
Copyright 2000-2008 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information Send comments to webmaster@clotcare.com. This site looks best when viewed with Microsoft Internet Explorer You can download the latest version of Internet Explorer from Microsoft's website. |
||||||||||||||||||||||||